Supernus (SUPN) Rule 144 Filing for 25,000 Shares valued $1.2M
Rhea-AI Filing Summary
Notice of proposed sale under Rule 144 for Supernus Pharmaceuticals, Inc. (SUPN) reports an intended sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,200,000.00. The shares were acquired on 05/01/2012 as an in-kind distribution from NEA Partners. The filing lists total shares outstanding as 56,073,088, and an approximate sale date of 10/09/2025 on the NASDAQ. The filer also disclosed recent Rule 10b5-1 executed sales by Charles Newhall totaling 6,000 shares across three trades on 08/22/2025, 08/25/2025, and 08/27/2025
Positive
- Brokered sale through Morgan Stanley indicates orderly execution channel for the 25,000 shares
- Acquisition documented (in-kind distribution from NEA Partners on 05/01/2012), supporting ownership provenance
Negative
- Insider selling activity: recent Rule 10b5-1 sales of 3,588, 1,412, and 1,000 shares occurred in 08/2025, totaling 6,000 shares
- Represents potential dilution signal: 25,000 shares equal a measurable sale against 56,073,088 outstanding shares
Insights
Planned sale is formally disclosed and appears executed via broker and 10b5-1 plans.
The filing documents a proposed Rule 144 sale of 25,000 common shares valued at $1.2M, acquired by in-kind distribution from NEA Partners on 05/01/2012. The transaction is routed through Morgan Stanley Smith Barney LLC and slated for trading on NASDAQ on 10/09/2025.
Dependencies and compliance risks include adherence to Rule 144 timing/volume limits and the representational statement about no undisclosed material information. Recent 10b5-1 sales by the same account—totaling 6,000 shares in 08/2025—indicate prior executed sale activity; confirm plan adoption dates and broker instructions to validate Rule 10b5-1 reliance.